gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLCgastro-j-993Research ArticleОБМЕН ОПЫТОМEXCHANG OF EXPERIENCEСовременные аспекты диагноcтики и лечения инфекции H. pylori в свете профилактики рака желудкаModern aspects of diagnostics and treatment of H. pylori infection from standpoint of stomach cancer prophylaxisШептулинА. А.SheptulinA. A.

Шептулин Аркадий Александрович — доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней 

119991, Москва, ул. Погодинская, д. 1, стр. 1. 

Sheptulin Arkady A — MD, PhD, professor, Chair of internal diseases propedeutics, medical faculty

119991, Moscow, Pogodinskaya street, 1, bld 1. 

arkalshep@gmail.comЛапинаТ. Л.LapinaT. L.ГБОУ ВПО «Первый Московский государственный медицинский университет им. И. М. Сеченова» Минздрава РоссииРоссияState educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian FederationRussian Federation2015010320152518085Copyright © Шептулин А.А., Лапина Т.Л., 20152015Шептулин А.А., Лапина Т.Л.Sheptulin A.A., Lapina T.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/993

Цель обзора. Обсудить современные аспекты диагностики и лечения инфекции H. pylori в свете профилактики рака желудка по итогам устных и стендовых докладов, представленных на XXVII Международном рабочем совещании Европейской группы по изучению Helicobacter.Основные положения. Основное внимание было уделено связи H. pylori с раком желудка и эрадикации инфекции как мере профилактики развития злокачественной патологии. Представлены данные о связи H. pylori с другими, в том числе и негастроэнтерологическими заболеваниями. Дана сравнительная оценка эффективности различных схем эрадикационной терапии. Согласно заключению большинства работ и данным мета-аналитических исследований, наиболее эффективными в настоящее время являются схемы квадротерапии с препаратами висмута и без них.Заключение. Для оценки роли инфекции H. pylori в развитии различных заболеваний, а также оптимизации лечения больных требуются дальнейшие исследования.

The aim of review

The aim of review. To discuss modern aspects of diagnostics and treatment of H. pylori infection in relation of stomach cancer prophylaxis according to data of oral and poster presentations, delivered at XXVII International workshop of the European Helicobacter Study Group.

Summary

Summary. The main attention has been given to relation of H. pylori infection to stomach cancer and eradications of infection as a mean of malignancy prevention. Data on relation of H. pylori to other diseases, including non-gastroenterological disorders are presented. Comparative estimation of efficacy of different modes of eradication therapy is given. According to conclusion of the majority of publications and data of meta-analyses, nowadays both bismuth-based and bismuth-free quadrotherapy are considered as the most effective treatment algorithms.

Conclusion

Conclusion. For estimation of role of H. pylori infection in development of various diseases, and to improve management of patients further studies are required.

диагностикапрофилактикаH. pyloriрак желудкаdiagnosticsprophylaxisH. pyloristomach cancerReferencesVarbanova M., Frauenschlager K., Langner S., Link A., Malfertheiner P. Active gastritis in Helicobacter pylori negative patients: A new entity? Helicobacter 2014; 19 (Suppl. 1):160.Varbanova M., Frauenschlager K., Langner S., Link A., Malfertheiner P. Active gastritis in Helicobacter pylori negative patients: A new entity? Helicobacter 2014; 19 (Suppl. 1):160.Dimoulios F., Tsikrika E., Kontotasios K., Panteleakis K. Protective role of Helicobacter pylori infection against severe reflux esophagitis. Helicobacter 2014; 19 (Suppl. 1); Abstract no. Р08.09:117.Dimoulios F., Tsikrika E., Kontotasios K., Panteleakis K. Protective role of Helicobacter pylori infection against severe reflux esophagitis. Helicobacter 2014; 19 (Suppl. 1); Abstract no. Р08.09:117.Tsukanov V. V., Onuchina E. V., Vasyutin A. V., Amelchugova O. S., Tonkikh J. L. H. pylori eradication does not affect the GERD course in elderly patients: the results of a 5-year prospective study. Helicobacter 2014; 19 (Suppl. 1):116.Tsukanov V. V., Onuchina E. V., Vasyutin A. V., Amelchugova O. S., Tonkikh J. L. H. pylori eradication does not affect the GERD course in elderly patients: the results of a 5-year prospective study. Helicobacter 2014; 19 (Suppl. 1):116.Murphy G., Michel A., Taylor P. R., Albanes D., et al. Serological association of Helicobacter pylori proteins and biliary tractcancer in the ATBC study. Helicobacter 2014; 19 (Suppl. 1):87.Murphy G., Michel A., Taylor P. R., Albanes D., et al. Serological association of Helicobacter pylori proteins and biliary tractcancer in the ATBC study. Helicobacter 2014; 19 (Suppl. 1):87.Queiroz D. M.M., Braga L. L.C., Perry S. L., Rocha A. M.C., Rocha J. A., Crabtree J. E. H. pylori (HP) infection with CagA-positive strains is associated with anemia in infants and toddlers. Helicobacter 2014; 19(Suppl. 1):81.Queiroz D. M.M., Braga L. L.C., Perry S. L., Rocha A. M.C., Rocha J. A., Crabtree J. E. H. pylori (HP) infection with CagA-positive strains is associated with anemia in infants and toddlers. Helicobacter 2014; 19(Suppl. 1):81.Kori M., Klein-Daniel R., Yahav J. A high prevalence of Helicobacter pylori infection among children with inflammatory bowel disease. Helicobacter 2014; 19 (Suppl. 1):118.Kori M., Klein-Daniel R., Yahav J. A high prevalence of Helicobacter pylori infection among children with inflammatory bowel disease. Helicobacter 2014; 19 (Suppl. 1):118.Zaika S., Paliy I., Vavrinchuck V. The influence of Helicobacter pylori on lipid metabolism in patient with coronary heart disease. Helicobacter 2014; 19 (Suppl. 1):116.Zaika S., Paliy I., Vavrinchuck V. The influence of Helicobacter pylori on lipid metabolism in patient with coronary heart disease. Helicobacter 2014; 19 (Suppl. 1):116.Franceschi F., Tortora A., Roberto M., Niccoli G., et al. Role of CagA-positive strains of H. pylori in acute myocardial infarction with ST-segment elevation. Helicobacter 2014; 19 (Suppl. 1):83.Franceschi F., Tortora A., Roberto M., Niccoli G., et al. Role of CagA-positive strains of H. pylori in acute myocardial infarction with ST-segment elevation. Helicobacter 2014; 19 (Suppl. 1):83.Bugli P., Franceschi F., Tinelli G., Cacaci M., et al. Human antibody response against Helicobacter pylori CagA may play a role in atherosclerotic-related disease through molecular mimicry mechanisms. Helicobacter 2014; 19 (Suppl. 1):117.Bugli P., Franceschi F., Tinelli G., Cacaci M., et al. Human antibody response against Helicobacter pylori CagA may play a role in atherosclerotic-related disease through molecular mimicry mechanisms. Helicobacter 2014; 19 (Suppl. 1):117.Di Simone N., Tersigni C., di Nicuolo F., Castellani R., et al. Helicobacter pylori and preeclampsia: role of antiCagA antibodies on placental development. Helicobacter 2014; 19 (Suppl. 1):88.Di Simone N., Tersigni C., di Nicuolo F., Castellani R., et al. Helicobacter pylori and preeclampsia: role of antiCagA antibodies on placental development. Helicobacter 2014; 19 (Suppl. 1):88.Burkov S. G., Bordin D., Markina N. F., Sharapova E. I. H. pylori and clinical course of pregnancy. Helicobacter 2014; 19 (Suppl. 1):115.Burkov S. G., Bordin D., Markina N. F., Sharapova E. I. H. pylori and clinical course of pregnancy. Helicobacter 2014; 19 (Suppl. 1):115.Moretti E., Collodei G., Campagna M., Sonelli S., Iacoponi F., Figura N. Semen levels of interleikin-6 and tumor necrosis factor-α are increased in CagA positive H. pylori infection and may cause sperm alterations. Helicobacter 2014; 19 (Suppl. 1):88.Moretti E., Collodei G., Campagna M., Sonelli S., Iacoponi F., Figura N. Semen levels of interleikin-6 and tumor necrosis factor-α are increased in CagA positive H. pylori infection and may cause sperm alterations. Helicobacter 2014; 19 (Suppl. 1):88.Asaoka D., Nagahara A., Shimada Y., Osada T., Hojo M., Watanabe S. The relationship between H. pylori infection and osteoporosis in Japan. Helicobacter 2014; 19 (Suppl. 1):115.Asaoka D., Nagahara A., Shimada Y., Osada T., Hojo M., Watanabe S. The relationship between H. pylori infection and osteoporosis in Japan. Helicobacter 2014; 19 (Suppl. 1):115.Roubaud-Baudron C., Blaszczyk L., Varon C., Chambonnier L., et al. Does Helicobacter pylori infection impact the course of Alzheimer’s disease? An animal study. Helicobacter 2014; 19 (Suppl. 1):87.Roubaud-Baudron C., Blaszczyk L., Varon C., Chambonnier L., et al. Does Helicobacter pylori infection impact the course of Alzheimer’s disease? An animal study. Helicobacter 2014; 19 (Suppl. 1):87.McNicholl A.G., Gassbarrini A., Tepes B., Lerang F., et al. Pan-European registry on H. pylori management (HP-EUREG): first-line treatments. Helicobacter 2014; 19 (Suppl. 1):129.McNicholl A.G., Gassbarrini A., Tepes B., Lerang F., et al. Pan-European registry on H. pylori management (HP-EUREG): first-line treatments. Helicobacter 2014; 19 (Suppl. 1):129.McNicholl A.G., Catala-Lopez F., Tobias A., Gisbert P. A network meta-analysis of first-line H. pylori eradication regimens. Helicobacter 2014; 19 (Suppl. 1):79.McNicholl A.G., Catala-Lopez F., Tobias A., Gisbert P. A network meta-analysis of first-line H. pylori eradication regimens. Helicobacter 2014; 19 (Suppl. 1):79.Georgopoulos S. D., Xirouchakis E., Zampeli E., Martines-Gonsales B., et al. A randomised study comparing 10 days concomitant and sequential treatments for the eradication of Helicobacter pylori, in a high claritrimycin resistance area. Helicobacter 2014; 19 (Suppl. 1):80.Georgopoulos S. D., Xirouchakis E., Zampeli E., Martines-Gonsales B., et al. A randomised study comparing 10 days concomitant and sequential treatments for the eradication of Helicobacter pylori, in a high claritrimycin resistance area. Helicobacter 2014; 19 (Suppl. 1):80.Kim J., Kim J., Kim B., Kim H., et al. Triple therapy, sequential therapy, and concomitant therapy for Helicobacter pylori infection in Korea: a multicenter, randomized, controlled trial. Helicobacter 2014; 19(Suppl. 1):80.Kim J., Kim J., Kim B., Kim H., et al. Triple therapy, sequential therapy, and concomitant therapy for Helicobacter pylori infection in Korea: a multicenter, randomized, controlled trial. Helicobacter 2014; 19(Suppl. 1):80.Nyssen O. P., McNicholl A.G., Megraud F., Savarino V., et al. Meta-analysis of sequential versus standard triple therapy for Helicobacter pylori eradication: final results of a Cochrane systematic review. Helicobacter 2014; 19 (Suppl. 1):129.Nyssen O. P., McNicholl A.G., Megraud F., Savarino V., et al. Meta-analysis of sequential versus standard triple therapy for Helicobacter pylori eradication: final results of a Cochrane systematic review. Helicobacter 2014; 19 (Suppl. 1):129.Losurdo G., Giorgio F., Monno R., di Leo A., Ierardi E. Sequential versus prolonged triple therapy meta-analysis may be influenced by «geographical weighting». Helicobacter 2014; 19 (Suppl. 1):131.Losurdo G., Giorgio F., Monno R., di Leo A., Ierardi E. Sequential versus prolonged triple therapy meta-analysis may be influenced by «geographical weighting». Helicobacter 2014; 19 (Suppl. 1):131.Zakharova N., Savilova I. Efficacy of modified triple therapy with bismuth substrate as first-line therapy to eradicate H. pylori in Saint-Pitersburg population. Helicobacter 2014; 19 (Suppl. 1):140Zakharova N., Savilova I. Efficacy of modified triple therapy with bismuth substrate as first-line therapy to eradicate H. pylori in Saint-Pitersburg population. Helicobacter 2014; 19 (Suppl. 1):140Moon B. S. Comparison of the efficacy of 10 day-triple therapy-based, bismuth-containing quadruple therapy with sequental therapy and concomitant therapy of Helicobacter pylori. Helicobacter 2014; 19 (Suppl. 1):133.Moon B. S. Comparison of the efficacy of 10 day-triple therapy-based, bismuth-containing quadruple therapy with sequental therapy and concomitant therapy of Helicobacter pylori. Helicobacter 2014; 19 (Suppl. 1):133.Jang B., Kim S., Lee S., Yang C. Comparison of 10-day sequental therapy with bismuth based quadruple therapy for second line Helicobacter pylori eradication. Helicobacter 2014; 19 (Suppl. 1):138.Jang B., Kim S., Lee S., Yang C. Comparison of 10-day sequental therapy with bismuth based quadruple therapy for second line Helicobacter pylori eradication. Helicobacter 2014; 19 (Suppl. 1):138.Lv Z., Xie Y., Wang F., Zheng H., et al. The efficacy and safety of probiotics as adjuvant agent for Helicobacter pylori infection: an meta-analysis. Helicobacter 2014; 19 (Suppl. 1):133.Lv Z., Xie Y., Wang F., Zheng H., et al. The efficacy and safety of probiotics as adjuvant agent for Helicobacter pylori infection: an meta-analysis. Helicobacter 2014; 19 (Suppl. 1):133.Mahachai V., Ratanachuek T., Myint T., Pittayanon R., et al. Antibiotic resistant pattern of Helicobacter pylori infection in the south and southeast Asian countries. Helicobacter 2014; 19 (Suppl. 1):146.Mahachai V., Ratanachuek T., Myint T., Pittayanon R., et al. Antibiotic resistant pattern of Helicobacter pylori infection in the south and southeast Asian countries. Helicobacter 2014; 19 (Suppl. 1):146.Alarcon T., Saez S., Merchan B., Rubio B., Gomez de Olea F., Ramirez E. Antimicrobial resistance in Helicobacter pylori and its relationship with consumtion of antibiotics. Helicobacter 2014; 19 (Suppl. 1):146.Alarcon T., Saez S., Merchan B., Rubio B., Gomez de Olea F., Ramirez E. Antimicrobial resistance in Helicobacter pylori and its relationship with consumtion of antibiotics. Helicobacter 2014; 19 (Suppl. 1):146.Martinez-Gonzales B., Papadokas K., Psarrakos P., Roma E., et al. High rate of clarithromycin resistance in Helicobacter pylori clinical isolates obtained from children in Greece: a retrospective study, 2000-2013. Helicobacter 2014; 19 (Suppl. 1):148.Martinez-Gonzales B., Papadokas K., Psarrakos P., Roma E., et al. High rate of clarithromycin resistance in Helicobacter pylori clinical isolates obtained from children in Greece: a retrospective study, 2000-2013. Helicobacter 2014; 19 (Suppl. 1):148.Siavoshi F., Hosseini F., Shahreza S., Khalili samani S., Afshar B. Increase in the resistance rates of H. pylori isolates after 5 years. Helicobacter 2014; 19(Suppl. 1):153.Siavoshi F., Hosseini F., Shahreza S., Khalili samani S., Afshar B. Increase in the resistance rates of H. pylori isolates after 5 years. Helicobacter 2014; 19(Suppl. 1):153.Martins G. M., Lima K. S., Cota B. D., Sanches B. S.F., Moretzsohn L. D., Coehlo L. G.V. Molecular detection of clarithromycin and fluoroquinolones resistance in Helicobacter pylori infection, directly applied to gastric biopsies, in a Brazilian urban population. Helicobacter 2014; 19 (Suppl. 1):150.Martins G. M., Lima K. S., Cota B. D., Sanches B. S.F., Moretzsohn L. D., Coehlo L. G.V. Molecular detection of clarithromycin and fluoroquinolones resistance in Helicobacter pylori infection, directly applied to gastric biopsies, in a Brazilian urban population. Helicobacter 2014; 19 (Suppl. 1):150.Mandkhai B., Munkhdelger Y., Bira N., Sarantuya J. Drug resistant H. pylori strains isolated in Mongolia. Helicobacter 2014; 19 (Suppl. 1):151.Mandkhai B., Munkhdelger Y., Bira N., Sarantuya J. Drug resistant H. pylori strains isolated in Mongolia. Helicobacter 2014; 19 (Suppl. 1):151.

The authors declare that there are no conflicts of interest present.